Completed PHASE2 INTERVENTIONAL 2-arm NCT01135108

Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Spinal Cord Injury

A Double-Blind, Randomized, Placebo-Controlled, Single-Dose Two-Period Crossover Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Spinal Cord Injury

Sponsor: KAI Pharmaceuticals

Conditions Spinal Cord Injury

Interventions KAI-1678 Placebo

Updated 6 times since 2017 Last updated: Aug 28, 2025 Started: Mar 31, 2009 Primary completion: Mar 31, 2010 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Spinal Cord Injury, this trial is completed. The trial is conducted by KAI Pharmaceuticals and has accumulated 6 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Oct 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

KAI Pharmaceuticals
Trident Clinical Research Pty Ltd

Data source: KAI Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sydney, Australia